Evercore ISI Group Boosts Abbott Laboratories Price Target to $145.00

Abbott Laboratories' (ABT) price target has been raised by Evercore ISI Group to $145.00, up from $140.00, reflecting a 3.57% increase. The analyst group maintained its "Outperform" rating for the company. The average target price for ABT is $142.14, with a high estimate of $159.00 and a low estimate of $120.12. The average target implies an upside of 6.31% from the current price.

Abbott Laboratories' (ABT) price target has been raised by Evercore ISI Group to $145.00, up from $140.00, reflecting a 3.57% increase. The analyst group maintained its "Outperform" rating for the company. The average target price for ABT is $142.14, with a high estimate of $159.00 and a low estimate of $120.12. The average target implies an upside of 6.31% from the current price [1].

The increase in price target comes amidst a strong analyst consensus rating for ABT. According to TipRanks, the consensus rating is a Strong Buy, with a $136.89 average price target, implying a 2.74% upside from current levels [1]. Additionally, Oppenheimer reiterated a Buy rating on the stock with a $140.00 price target [1].

Evercore ISI Group's analyst, Vijay Kumar, who covers the Healthcare sector, maintained a Buy rating on ABT with a price target of $145.00. Kumar has an average return of 1.3% and a 46.99% success rate on recommended stocks [1]. The company has seen a one-year high of $141.23 and a one-year low of $99.71. Currently, Abbott Laboratories has an average volume of 6.59M shares traded daily [1].

The recent corporate insider activity shows a negative sentiment, with 48 insiders selling their shares over the past quarter. Most recently, in May 2025, Sally Blount, a Director at ABT, sold 2,600 shares for a total of $337,116.00 [1].

Abbott Laboratories is expected to meet or exceed Wall Street’s targets for the second quarter, keeping the company on track to achieve its 2025 guidance targets. The company has demonstrated solid operational performance with a P/E ratio of 17.02 and revenue growth of 5% [3].

The company's strong operating momentum and several new growth drivers, such as TriClip in the US market and Volt in Europe, contribute to the optimistic outlook [3]. Abbott Laboratories has maintained dividend payments for 55 consecutive years, showcasing its financial stability [3].

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/ABT-N/pressreleases/33302590/evercore-isi-reaffirms-their-buy-rating-on-abbott-laboratories-abt/
[3] https://www.investing.com/news/analyst-ratings/abbott-labs-stock-price-target-reiterated-at-145-by-td-cowen-on-strong-outlook-93CH-4132346